NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q3 FY23 Financial Results Earnings Call04-02-2023
04-02-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificate01-02-2023
NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for To Consider The Unaudited Financial Results For The Quarter Ended 31St December 2022 And To Consider The Third Interim Dividend, If Any
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 ,inter alia, to consider and approve the unaudited financial results for the quarter ended 31st December 2022 and to consider the third interim dividend, if any31-01-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificates19-01-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate11-01-2023
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended December 31, 202211-01-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates28-12-2022
NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for V C Nannapaneni20-12-2022
Natco Pharma's crop care solutions likely to support earnings growth
Analysts remain optimistic on Natco's future profitability backed by the traction in CTPR and revlimid sales and recovery in domestic formulation06-12-2022